Therapeutic Drug Monitoring of Posaconazole: an Update

Bart G J Dekkers; Martijn Bakker; Kim C M van der Elst; Marieke G G Sturkenboom; Anette Veringa; Lambert F R Span; Jan-Willem C Alffenaar

doi:10.1007/s12281-016-0255-4

Therapeutic Drug Monitoring of Posaconazole: an Update

Bart G J Dekkers
, Martijn Bakker
, Kim C M van der Elst
, Marieke G G Sturkenboom
, Anette Veringa
, Lambert F R Span
, Jan-Willem C Alffenaar

Research output: Contribution to journal › Review article › peer-review

Abstract

Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.

Original language	English
Pages (from-to)	51-61
Number of pages	11
Journal	Current fungal infection reports
Volume	10
DOIs	https://doi.org/10.1007/s12281-016-0255-4
Publication status	Published - 2016
Externally published	Yes

Access to Document

10.1007/s12281-016-0255-4

Cite this

@article{4b14d0457cfb4b528196d54a64c73fcd,

title = "Therapeutic Drug Monitoring of Posaconazole: an Update",

abstract = "Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.",

author = "Dekkers, \{Bart G J\} and Martijn Bakker and \{van der Elst\}, \{Kim C M\} and Sturkenboom, \{Marieke G G\} and Anette Veringa and Span, \{Lambert F R\} and Alffenaar, \{Jan-Willem C\}",

year = "2016",

doi = "10.1007/s12281-016-0255-4",

language = "English",

volume = "10",

pages = "51--61",

journal = "Current fungal infection reports",

issn = "1936-3761",

publisher = "Springer",

}

TY - JOUR

T1 - Therapeutic Drug Monitoring of Posaconazole

T2 - an Update

AU - Dekkers, Bart G J

AU - Bakker, Martijn

AU - van der Elst, Kim C M

AU - Sturkenboom, Marieke G G

AU - Veringa, Anette

AU - Span, Lambert F R

AU - Alffenaar, Jan-Willem C

PY - 2016

Y1 - 2016

N2 - Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.

AB - Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.

U2 - 10.1007/s12281-016-0255-4

DO - 10.1007/s12281-016-0255-4

M3 - Review article

C2 - 27358662

SN - 1936-3761

VL - 10

SP - 51

EP - 61

JO - Current fungal infection reports

JF - Current fungal infection reports

ER -

Therapeutic Drug Monitoring of Posaconazole: an Update

Abstract

Access to Document

Fingerprint

Cite this